Statistics from Altmetric.com
The antinuclear antibody (ANA) test is one of the most common autoimmunity blood tests, which plays a major role in the diagnosis of several connective tissue diseases (CTDs), including scleroderma/systemic sclerosis and systemic lupus erythematosus (SLE).1 We performed a brief investigation to examine the performance of ANA in ANA-associated CTDs (ANA-CTD) at one Australian teaching tertiary hospital. All ANAs ordered at the Royal Hobart Hospital pathology laboratory in a 6.5-year period from July 2008 to December 2014 were identified. July 2008 was the first point in which ANA tests were performed onsite using human epithelial cells (HEp-2) substrates and was therefore used as the starting point. Only the first episode for each patient was identified to avoid duplicates in entries.
There were a total of 4500 valid ANA cases during this timeframe, with …